AbCellera Results Presentation Deck

FINANCIALS FULL YEAR 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 15 Large diversified portfolio in next-gen antibody therapies. 35% human health (TBD) n = 52 57% oncology 55% human health (known) n = 81 15% neurology 11% immunology 5% ophthalmology 4% infectious disease 2% dermatology 6% other 10% animal health n = 15 148 Partner-Initiated Programs under contract with downstream participation are diversified across these therapeutic areas 42% oncology T cell-engagers n = 5 50% undisclosed GPCRs & ion channels n = 6 100% human health n = 12 8% fectious disease pandemic response 12 Pre-Partnered Programs started across these therapeutic areas n=1

View entire presentation